41-2 [PTA-226] (ATCC® CRL-2695™)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte

Permits Notice: Necessary Permits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Disease Carcinoma
Applications
Products: immunoglobulin; monoclonal antibody; against CDCP1 (SIMA135).
The antibody may be useful for treating and diagnosing metastatic tumors.
Storage Conditions liquid nitrogen vapor phase
Derivation
Spleen cells were fused with NS0 myeloma cells.
Comments
Products: immunoglobulin; monoclonal antibody; against CDCP1 (SIMA135).
The antibody identifies SIMA135/CDCP1 (subtractive immunization M(+)HEp3 associated 135 kDa protein/CUB domain containing protein 1) [PubMed: 12660814].
Animals were immunized with metastatic human epidermoid carcinoma (HEp-3) cells by subtractive immunization.
Spleen cells were fused with NS0 myeloma cells.
The antibody may be useful for treating and diagnosing metastatic tumors.
A culture of 41-2 was deposited with the ATCC as PTA-226 in June of 1999. The cell line grown at ATCC is available as CRL-2696. The original patent deposit is available as PTA-226.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium:
  • O.1 mM Non-Essential Amino Acids (NEAA)
  • fetal bovine serum to a final concentration of 10%
Subculturing
Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Do not allow the cell concentration to exceed 1 x 10(6) cells/ml.
Interval: Maintain cultures at a cell concentration between 1 X 10(5) and 1 x 10(6) cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium supplemented with 7.5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Isotype mouse IgG1 kappa
Name of Depositor Research Fndn. SUNY
References

Testa JE, et al. Monoclonal antibodies that recognize antigens associated with tumor metastasis. US Patent 6,245,898 dated Jun 12 2001

Testa JE, et al. Monoclonal antibodies that recognize antigens associated with tumor metastasis. US Patent 6,498,014 dated Dec 24 2002

Hooper JD, et al. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 22: 1783-1794, 2003. PubMed: 12660814

Permits Notice: Necessary Permits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
MSDS
MSDS
References

Testa JE, et al. Monoclonal antibodies that recognize antigens associated with tumor metastasis. US Patent 6,245,898 dated Jun 12 2001

Testa JE, et al. Monoclonal antibodies that recognize antigens associated with tumor metastasis. US Patent 6,498,014 dated Dec 24 2002

Hooper JD, et al. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene 22: 1783-1794, 2003. PubMed: 12660814